Literature DB >> 23983433

High level of preoperative carbohydrate antigen 19-9 is a poor survival predictor in gastric cancer.

A Ra Choi1, Jun Chul Park, Jie-Hyun Kim, Sung Kwan Shin, Sang Kil Lee, Yong Chan Lee, Jae Bock Chung.   

Abstract

AIM: To assess the clinical significance and the prognostic value of preoperative serum carbohydrate antigen 19-9 (CA 19-9) level in gastric cancer.
METHODS: Between January 2005 and December 2006, 1960 patients underwent surgery for histologically confirmed gastric cancer. Of these, 163 patients had elevated serum levels of CA 19-9 preoperatively, and 1628 patients had normal serum levels of CA 19-9 preoperatively. For this study, 325 patients were selected from the group of 1628 patients by age, sex, and cancer stage to serve as controls. Statistically significant differences in survival rates were calculated using the log-rank test. A P value less than 0.05 was considered statistically significant and was determined using SAS software.
RESULTS: The baseline characteristics showed some differences between the two groups with regard to histology. Overall survival (OS) in the elevated and non-elevated group was 37.90 and 68.67 mo, respectively (P < 0.001). N stage (P = 0.001) was a significant predictor of disease-free survival by multivariate analysis. Also, N stage (P < 0.001), and the presence of peritoneal metastasis (P < 0.001) remained independent factors in predicting OS by multivariate analysis. Additionally, preoperative serum CA 19-9 levels were significantly associated with OS in univariate (P = 0.009) and multivariate (P = 0.021) analyses.
CONCLUSION: Serum CA 19-9 can be considered an independent prognostic factor in predicting OS in patients anticipating surgery for gastric cancer.

Entities:  

Keywords:  Carbohydrate antigen 19-9; Disease-free survival; Gastric cancer; Overall survival

Mesh:

Substances:

Year:  2013        PMID: 23983433      PMCID: PMC3752564          DOI: 10.3748/wjg.v19.i32.5302

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  42 in total

1.  Discovery of diagnostic serum biomarkers of gastric cancer using proteomics.

Authors:  Katie Wing-Kei Lam; Samuel Chun-Lap Lo
Journal:  Proteomics Clin Appl       Date:  2008-02       Impact factor: 3.494

2.  The prognostic value of serum and immunohistochemical tumour markers in advanced gastric cancer.

Authors:  A Webb; P Scott-Mackie; D Cunningham; A Norman; J Andreyev; M O'Brien; J Bensted
Journal:  Eur J Cancer       Date:  1996-01       Impact factor: 9.162

3.  The prognostic significance of preoperative serum CA 19-9 in patients with resectable gastric carcinoma: comparison with CEA.

Authors:  N Duraker; A N Celik
Journal:  J Surg Oncol       Date:  2001-04       Impact factor: 3.454

4.  Prognostic value of carcinoembryonic antigen, CA 19-9 and CA 72-4 in gastric carcinoma.

Authors:  M J Gaspar; I Arribas; M C Coca; M Díez-Alonso
Journal:  Tumour Biol       Date:  2001 Sep-Oct

5.  CEA and CA 19.9 in gastric juice and serum: an aid in the diagnosis of gastric carcinoma?

Authors:  J D Harrison; J Stanley; D L Morris
Journal:  Eur J Surg Oncol       Date:  1989-06       Impact factor: 4.424

6.  Gastric cancer: tumor markers as predictive factors for preoperative staging.

Authors:  Esther Uña Cidón; Rosa Bustamante
Journal:  J Gastrointest Cancer       Date:  2011-09

7.  AFP-producing gastric carcinoma: multivariate analysis of prognostic factors in 270 patients.

Authors:  Yosuke Adachi; Junko Tsuchihashi; Norio Shiraishi; Kazuhiro Yasuda; Tsuyoshi Etoh; Seigo Kitano
Journal:  Oncology       Date:  2003       Impact factor: 2.935

8.  A uniform residual tumor (R) classification: integration of the R classification and the circumferential margin status.

Authors:  Christian Wittekind; Carolyn Compton; Phil Quirke; Iris Nagtegaal; Susanne Merkel; Paul Hermanek; Leslie H Sobin
Journal:  Cancer       Date:  2009-08-01       Impact factor: 6.860

9.  Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen.

Authors:  R Muraro; M Kuroki; D Wunderlich; D J Poole; D Colcher; A Thor; J W Greiner; J F Simpson; A Molinolo; P Noguchi
Journal:  Cancer Res       Date:  1988-08-15       Impact factor: 12.701

10.  Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer.

Authors:  M Ychou; J Duffour; A Kramar; S Gourgou; J Grenier
Journal:  Dis Markers       Date:  2000       Impact factor: 3.434

View more
  14 in total

1.  Prognostic value of neutrophil to lymphocyte ratio for gastric cancer.

Authors:  Zhi-De Hu; Yuan-Lan Huang; Bao-Dong Qin; Qing-Qin Tang; Min Yang; Ning Ma; Hai-Tao Fu; Ting-Ting Wei; Ren-Qian Zhong
Journal:  Ann Transl Med       Date:  2015-03

2.  Elevated serum CA 19-9 at screening tests: underlying conditions and role of abdominopelvic CT.

Authors:  Ji Yang Kim; Se Hyung Kim; Soo Young Kim
Journal:  Eur Radiol       Date:  2014-08-12       Impact factor: 5.315

3.  Influence of prognostic nutritional index and tumor markers on survival in gastric cancer surgery patients.

Authors:  Hiroaki Saito; Yusuke Kono; Yuki Murakami; Hirohiko Kuroda; Tomoyuki Matsunaga; Yoji Fukumoto; Tomohiro Osaki
Journal:  Langenbecks Arch Surg       Date:  2017-03-15       Impact factor: 3.445

4.  An Alternative Method for Screening Gastric Cancer Based on Serum Levels of CEA, CA19-9, and CA72-4.

Authors:  Junxiu Yu; Wanlei Zheng
Journal:  J Gastrointest Cancer       Date:  2018-03

5.  Differences and correlation of serum CEA, CA19-9 and CA72-4 in gastric cancer.

Authors:  Junxiu Yu; Shuguang Zhang; Bingbo Zhao
Journal:  Mol Clin Oncol       Date:  2015-12-15

6.  Clinical significance of serum thymus and activation-regulated chemokine in gastric cancer: potential as a serum biomarker.

Authors:  Jong-Baeck Lim; Do-Kyun Kim; Hye Won Chung
Journal:  Cancer Sci       Date:  2014-10-01       Impact factor: 6.716

Review 7.  Selectin Ligands Sialyl-Lewis a and Sialyl-Lewis x in Gastrointestinal Cancers.

Authors:  Marco Trinchera; Adele Aronica; Fabio Dall'Olio
Journal:  Biology (Basel)       Date:  2017-02-23

8.  Effectiveness of additional resection of the invasive cancer-positive proximal bile duct margin in cases of hilar cholangiocarcinoma.

Authors:  Wen-Jie Ma; Zhen-Ru Wu; Anuj Shrestha; Qin Yang; Hai-Jie Hu; Jun-Ke Wang; Fei Liu; Rong-Xing Zhou; Quan-Sheng Li; Fu-Yu Li
Journal:  Hepatobiliary Surg Nutr       Date:  2018-08       Impact factor: 7.293

Review 9.  Clinicopathologic and Prognostic Value of Serum Carbohydrate Antigen 19-9 in Gastric Cancer: A Meta-Analysis.

Authors:  Yong-xi Song; Xuan-zhang Huang; Peng Gao; Jing-xu Sun; Xiao-wan Chen; Yu-chong Yang; Cong Zhang; Hong-peng Liu; Hong-chi Wang; Zhen-ning Wang
Journal:  Dis Markers       Date:  2015-10-21       Impact factor: 3.434

10.  Prognostic value of diffuse splenic FDG uptake on PET/CT in patients with gastric cancer.

Authors:  Hai-Jeon Yoon; Bom Sahn Kim; Chang Mo Moon; Jang Yoo; Ko Eun Lee; Yemi Kim
Journal:  PLoS One       Date:  2018-04-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.